The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis.

. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with -mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with pre-treated -mutant CRC. We monitored patients in randomized, controlled studies who had advanced CRC and were undergoing second-line chemotherapy in addition to utilizing Bevacizumab, Ramucirumab or Aflibercept treatments. These data were pooled together with the data and results of -mutant patients enrolled in two phase III trials (TRIBE and TRIBE-2 study), who had been treated with second-line treatment both with or without Bevacizumab. Overall survival (OS), in relation to mutational status, was the primary focus. . Pooled analysis included 129 patients. Anti-angiogenics were found to have a significant advantage over the placebo in terms of OS (HR 0.50, 95%CI 0.29-0.85) ( = 0.01). . Our pooled analysis confirms the efficacy of anti-angiogenics in pre-treated -mutant CRC, establishing the combination of chemotherapy plus Bevacizumab or Ramucirumab or Aflibercept as a valid treatment option.